Oxygen-Enhanced MRI could sharpen radiotherapy for deadly brain cancers

NCT ID NCT07670455

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This study tests whether oxygen-enhanced MRI (OE-MRI) can identify low-oxygen (hypoxic) regions in high-grade gliomas, the most common and aggressive adult brain cancers. Twenty-five patients will undergo OE-MRI scans before, during, and after standard radiotherapy. Researchers will then use computer models to see if targeting those hypoxic areas with higher radiation doses could improve tumor control. The study does not change actual treatment—it is purely imaging and planning.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Oxygen-enhanced MRI (OE-MRI)

What this could lead to

If successful, this imaging technique could help doctors target radiotherapy more precisely to low-oxygen tumor areas, potentially improving treatment for aggressive brain cancers.

What could go wrong

This is a small, early-stage imaging study (25 participants) that only models higher radiation doses—it does not test actual treatment changes. The technique may not reliably detect hypoxia or improve outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA (GBM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer brain hypoxia - ischemia brain neoplasm glioblastoma Hypoxia, Brain malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••